ZURICH (Reuters) Sept 20 - Swiss drugmakerRoche Holding AG said on Thursday a European medical committee had recommended the reinstatement of its HIV drug Viracept's marketing authorisation.
The positive recommendation from the European Medicines Agency's Committee for Human Medicinal Products (CHMP) will now go to the European Commission for a final decision, Roche said in a statement.
Roche said in June the licence was being temporarily suspended pending a review by authorities.
The European Commission then suspended Viracept's licence due to the contamination of certain lots with ethyl mesilate.
"Roche fully intends to re-supply Viracept (nelfinavir) once the suspension is lifted," the company said. "However, it may take a few months for Viracept to be available again to prescribers and patients."
No comments:
Post a Comment